Morphine Injection Recall: One Lot May Contain Dilaudid Instead
Who this is for: Anyone who was recently hospitalized and received pain medication by injection, or who has a loved one currently in the hospital receiving IV pain relief. This recall involves a labeling mix-up between two different opioids, and knowing the details can help you ask the right questions.
What Happened
Fresenius Kabi is recalling one lot of its Simplist brand Morphine Sulfate Injection. The company found that some packages labeled as morphine 2 mg per 1 mL may actually contain a prefilled syringe of Dilaudid 0.5 mg per 0.5 mL instead.
Dilaudid, also called hydromorphone, is a different opioid than morphine. It is significantly more potent by weight. Fresenius Kabi announced the voluntary nationwide recall on August 4, 2026, and the FDA published the recall notice the following day.
Getting the wrong opioid is not a small error. Receiving a mislabeled package has a reasonable probability of causing serious health consequences, including life threatening respiratory depression and death. The patients at greatest risk include people who do not use opioids regularly, those with underlying respiratory conditions, and pediatric patients.
Why This Is Mainly a Hospital Story, Not a Home Story
This product is not something patients pick up at a pharmacy. It ships directly to hospitals and healthcare facilities, where clinical staff administer it.
The recalled product was distributed nationwide to distributors and wholesalers, and Fresenius Kabi is notifying its customers and arranging for the recalled product to be returned.
That means the direct action items fall on hospitals and healthcare workers, not on individual consumers. Still, if you or someone you love was hospitalized recently and received an injectable pain medication, this recall is worth understanding.
This is not the first mix-up style recall we have covered. If you want to see how a labeling error plays out with a food product instead of a medication, our Lidl cookie recall breakdown walks through a similar situation with undeclared allergens.
Affected Product Details
Here is exactly what is involved, in case a hospital or provider asks you to confirm information or you want to look up your own records.
| Detail | Information |
|---|---|
| Brand | Fresenius Kabi Simplist |
| Product | Morphine Sulfate Injection USP, 2 mg per 1 mL prefilled syringe |
| Lot number | 6402820 |
| Product code | 764411 |
| Unit-of-use NDC | 76045-004-01 |
| Unit-of-sale NDC | 76045-004-11 |
| Expiration date | December 2028 |
| First shipment date | January 29, 2026 |
| Last shipment date | June 9, 2026 |
The affected package is labeled Morphine Sulfate Injection 2 mg per 1 mL, but the syringe inside may actually be Dilaudid 0.5 mg per 0.5 mL.
What Healthcare Facilities Should Do
If a hospital or clinic has any units from lot 6402820, they should stop distributing, dispensing, or using that lot right away. Facilities are instructed to return all affected units to Fresenius Kabi.
Fresenius Kabi is notifying its distributors and customers directly and is arranging for the return of the recalled product. The full FDA recall notice has the complete details for facility compliance teams.
What to Do If You or a Family Member Was Recently Hospitalized
If you or a loved one received an injectable opioid for pain between late January and early June 2026, here are a few simple steps.
Ask the hospital directly. Call the facility’s patient safety or pharmacy department and ask whether lot 6402820 was used during the stay.
Watch for warning signs after the fact. If something felt off after receiving pain medication, such as unusual drowsiness, slowed or shallow breathing, or confusion, mention it to a physician.
Talk to your doctor if you have lingering concerns. A medication mix-up is rare, but if you believe you experienced a problem after receiving injectable pain relief, contact your healthcare provider so it can be documented and reviewed.
Do not try to identify the medication yourself. If you happen to have any paperwork or packaging from a hospital stay, do not attempt to open or test it. Contact the hospital or provider instead.
Why This Type of Mix-up Matters
Morphine and Dilaudid are sometimes confused because their names and packaging can look or sound similar in a fast-paced clinical setting. Fresenius Kabi has previously marketed its Simplist prefilled syringes as a way to help prevent exactly this kind of name confusion between hydromorphone and morphine.
That history is part of why this particular recall has drawn attention. The very product line built to reduce mix-up risk is the one involved here.
Frequently Asked Questions
Is this recall something I need to check my medicine cabinet for? No. This product is only used in hospitals and healthcare facilities. It is not sold or dispensed for home use.
Has anyone been harmed? No adverse events had been reported at the time the recall was announced.
How would I know if this affected me or a family member? The only way to know is to ask the hospital or facility directly whether lot 6402820 was among the medications used during your stay.
What is the difference between morphine and Dilaudid? Both are opioid pain medications, but Dilaudid (hydromorphone) is significantly more potent by weight than morphine. Receiving the wrong one, at the wrong dose, is what creates the safety risk described in this recall.
The Bottom Line
This recall centers on a labeling error, not a contamination or quality issue, but the stakes are still high because it involves two different opioids being confused with each other. If you or a family member had a hospital stay between late January and early June 2026 and received injectable pain medication, a quick call to the facility can confirm whether this lot was involved.
For more recall coverage like this one, check our General Health section, including our recent piece on the iceberg lettuce recall affecting products in 27 states. You can also visit the Your First 10 homepage for the latest health and safety updates.